MIR MedMira Inc

MedMira Inc. (MedMira) (TSXV:MIR) held its 2018 Annual General Meeting of Shareholders on January 31, 2018 in Halifax, Nova Scotia.  Incumbent Directors Mr. Hermes Chan and Dr. Shou-Ching Tang were re-elected and Ms. Lili Zhao was elected to the Board during the meeting.  Mr. Marvyn Robar chose not to stand for re-election to the MedMira Board of Directors.   

Ms. Zhao brings diverse experience in banking, education, publishing, and technology to the MedMira Board of Directors.  Ms. Zhao serves on the VALID advisory board at Procivis AG, a Zurich-based technology company and is the head of global partnerships at Brickblock Ltd, a distributed ledger technology company.  She is the founder of SilkChain GmbH, a Swiss consultancy firm specializing in FinTech.  Prior to her current roles, Ms. Zhao worked for HSBC Private Bank and Bank Vontobel AG in Zurich, Switzerland.  She holds a Master of Business Administration from the University of St. Gallen and graduated from University of London with a first class degree in Economics.

“Ms. Zhao has outstanding international business experience and we look forward to her valuable insights and contributions to the strategic direction of Company,” said Hermes Chan, Director and President & CEO, MedMira Inc.  “The Company thanks Mr. Robar for his service as Chairman of the Board.”

Shareholders also approved the appointment of Deloitte LLP as the Company’s auditors during the meeting.

MedMira granted 1,100,000 options to purchase common shares to Marvyn Robar, Hermes Chan, and Shou-Ching Tang as a part of the 2017 compensation package under the amended Stock Option Plan approved by shareholders at the 2016 Annual General & Special Meeting of Shareholders. Options were granted at an exercise price of $0.05 per share and exercisable for a period of three years ending January 31, 2021.

About MedMira

MedMira is the developer and owner of Rapid Vertical Flow (RVF) Technologyä. The Company’s rapid test applications built on RVF Technology provide hospitals, labs, clinics and individuals with instant diagnosis for diseases such as HIV and hepatitis C in just three easy steps. The Company’s tests are sold under the Reveal, Multiplo and Miriad brands in global markets. MedMira’s corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada and the Company has a sales and customer service office located the United States. For more information visit www.medmira.com. Follow us on Twitter and LinkedIn.

This news release contains forward-looking statements, which involve risk and uncertainties and reflect the Company’s current expectation regarding future events including statements regarding possible approval and launch of new products, future growth, and new business opportunities.  Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

MedMira Contacts:

Markus Meile, CFOTel: 902-450-1588   Email: m.meile@medmira.com

Andrea Young, Corporate CommunicationsTel: 902-450-1588Email: ayoung@medmira.com